LDN for Depression and Anxiety: What the 2026 Trial Actually Found

Low-dose naltrexone, commonly called LDN, is increasingly discussed in online mental-health, chronic-illness, and functional-medicine communities. Claims often focus on inflammation, endorphins, motivation, emotional resilience, or the possibility that one medication could improve pain, fatigue, mood, and weight at the same time.

The newest evidence requires a more careful conclusion.

A small 2017 proof-of-concept study reported an encouraging signal on some secondary depression measures. A larger randomized trial published in 2026 found that adjunctive LDN did not outperform placebo for moderate major depressive disorder after 12 weeks. Direct evidence for anxiety disorders is even thinner.

That does not mean no individual could ever report a mood change while taking LDN. It means LDN has not been established as an antidepressant, an anxiety treatment, a replacement for psychotherapy or standard medication, or a proven way to improve mood during GLP-1 treatment.

Considering LDN for a separate condition while managing depression, anxiety, or weight? Explore Scripx low-dose naltrexone care, review LDN medication interactions, or contact Scripx for a medication-coordination discussion. LDN should not replace mental-health evaluation, psychotherapy, antidepressant treatment, or crisis care.

Considering LDN? Scripx can help you understand personalized compounded low-dose naltrexone optionsafter a licensed prescriber determines that treatment is appropriate. LDN is off-label for POTS and should not replace diagnostic evaluation or established care.

Ready to Get Started?

Explore available treatment options and complete a secure health questionnaire for provider review.

View Products & Start Your Order →

Prescription medications require an individual medical evaluation and, when appropriate, a prescription from a licensed healthcare provider. Completing a questionnaire does not guarantee treatment or a prescription.

 

The Direct Answer: Is LDN Proven for Depression or Anxiety?

No. LDN is not FDA-approved to treat depression or anxiety, and current evidence does not establish it as an effective treatment for either condition.

For depression, two small randomized studies provide the most relevant direct evidence:

• A 2017 study randomized only 12 adults with breakthrough depressive symptoms while they were already taking selected antidepressant regimens. The primary depression-scale comparison did not reach statistical significance, although some secondary measures favored LDN.

• A 2026 study randomized 37 adults with moderate major depressive disorder who were receiving antidepressant treatment. After 12 weeks, LDN up to 4.5 mg daily did not outperform placebo on the primary depression outcome.

For anxiety, there is no adequate randomized trial establishing LDN as treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, or another primary anxiety disorder. Reports from multiple sclerosis, chronic-pain, or other populations cannot be relabeled as proof that LDN treats anxiety disorders.

Why the Mechanism Sounds More Certain Than the Outcome

Naltrexone is an opioid antagonist. At standard doses, oral naltrexone is FDA-approved for alcohol dependence and for blocking the effects of exogenous opioids as part of a comprehensive treatment plan. LDN uses substantially smaller, customized doses off label.

Proposed LDN mechanisms include temporary opioid-receptor blockade, changes in endogenous opioid signaling, microglial modulation, Toll-like receptor 4 activity, and reduced inflammatory signaling. Researchers have also studied inflammation as one possible contributor to some forms of major depressive disorder.

These are reasonable research questions. They are not clinical outcomes.

A mechanism cannot tell us whether a patient will achieve remission, whether anxiety will improve, whether suicidal thinking will decrease, whether an antidepressant can be stopped, or whether an LDN and GLP-1 combination will improve both mood and weight. Those questions require controlled human trials with meaningful endpoints.

What the 2017 Proof-of-Concept Study Found

The earlier randomized study enrolled 12 adults with recurrent major depressive disorder who had breakthrough symptoms while receiving selected antidepressant regimens with dopaminergic activity. Participants received naltrexone 1 mg twice daily or placebo for three weeks as an add-on treatment.

The primary outcome, the 17-item Hamilton Depression Rating Scale, improved more numerically with LDN, but the between-group comparison was not statistically significant, with a reported p value of 0.3. Some secondary Montgomery–Åsberg Depression Rating Scale measures favored LDN, with reported p values of 0.035.

The correct interpretation is not that the study proved LDN treats depression. It was a 12-person, short-duration proof-of-concept trial. Multiple outcomes were examined, the primary comparison was not significant, and every participant was already receiving an antidepressant regimen. The authors appropriately called for confirmation in larger studies.

Review the 2017 proof-of-concept study on PubMed.

What the 2026 Randomized Trial Found

The 2026 study provides the most important update for patients and clinicians.

Researchers randomized 37 adults with moderate major depressive disorder who were already receiving antidepressant treatment. Participants received LDN, titrated up to 4.5 mg daily, or inactive placebo for 12 weeks. The primary outcome was the Montgomery–Åsberg Depression Rating Scale, commonly abbreviated MADRS.

At 12 weeks, MADRS scores had fallen by an average of 10.5 points in the LDN group and 9.8 points in the placebo group. The adjusted between-group difference was essentially zero and was not statistically significant, with a reported p value of approximately 0.97.

LDN also did not improve high-sensitivity C-reactive protein, behavioral activation, quality of life, sickness symptoms, or the study's other exploratory mood measures. Baseline high-sensitivity C-reactive protein did not identify a group with a better LDN response.

Both groups improved. The trial did not show that LDN caused greater improvement than placebo.

The study was still small and does not answer every possible question about treatment-resistant depression or biomarker-defined subgroups. But a small study is not dismissed simply because its result is negative. The best current evidence does not support presenting adjunctive LDN as an established treatment for moderate major depressive disorder.

Read the 2026 randomized trial.

What About LDN for Anxiety?

The anxiety evidence is less direct than the depression evidence.

A 2022 study mailed surveys to a small group of people with multiple sclerosis during the COVID-19 pandemic. Participants prescribed LDN, alone or with a disease-modifying therapy, reported lower anxiety and depression scores than some participants using oral disease-modifying therapy.

That study may generate a hypothesis, but it was not a randomized anxiety-treatment trial. The groups were defined by existing treatment choices, symptoms were self-reported, the population had multiple sclerosis, and pandemic stress created an unusual context. Differences could reflect disease duration, baseline health, treatment selection, other medications, or unmeasured factors.

Anxiety or depression measures also appear as secondary outcomes in some chronic-pain and neurologic studies. Improvement in pain, sleep, fatigue, or daily function may influence mood scores. That does not establish a direct anti-anxiety effect.

The National Institute of Mental Health states that anxiety treatment commonly involves psychotherapy, medication, or both, selected according to the person's diagnosis, needs, preferences, and medical situation. LDN should not displace that evidence-based evaluation.

Review the multiple sclerosis survey and NIMH guidance on generalized anxiety disorder.

Evidence Snapshot: What Has Been Reported and What Remains Unproven

 

 

LDN Should Not Replace Established Depression or Anxiety Care

Depression and anxiety are broad clinical categories, not single symptoms. Low mood can occur with major depressive disorder, bipolar disorder, grief, trauma, substance use, sleep disorders, thyroid disease, medication effects, chronic pain, and many other conditions. Anxiety may reflect generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, trauma, a medication effect, withdrawal, or a medical condition.

That diagnostic distinction matters. For example, starting an antidepressant or another activating medication without recognizing bipolar disorder may worsen mood instability. Sedating medications, stimulants, steroids, thyroid therapies, substance withdrawal, and rapid changes in nutrition or sleep can also change symptoms.

NIMH describes depression treatment as psychotherapy, medication, or both, with brain-stimulation therapies as options in selected cases when initial treatments are insufficient. A qualified clinician can assess severity, safety, previous treatment response, bipolar-spectrum symptoms, substance use, medical contributors, and the need for urgent support.

LDN may be discussed for a separate off-label goal in an individual who also has depression or anxiety. That is different from telling the person that LDN will treat the psychiatric condition.

Read the NIMH depression treatment overview.

Can LDN Be Taken With an Antidepressant?

There is no universal answer for “an antidepressant.” The category includes medications with different mechanisms, interaction profiles, seizure risks, blood-pressure effects, liver considerations, discontinuation syndromes, and overdose risks.

The direct LDN depression studies evaluated LDN as an add-on to existing antidepressant treatment. That confirms that certain combinations have been studied in small research settings. It does not prove that every LDN-antidepressant combination is safe or beneficial.

Official oral naltrexone labeling states that formal interaction studies with drugs other than opioids have not been performed and advises caution with concomitant medications. A medication review should therefore identify:

• The exact antidepressant, dose, and duration

• Other bupropion-containing products

• Bipolar disorder, mania, psychosis, or seizure history

• Alcohol, benzodiazepine, sedative, or antiseizure-drug use and withdrawal risk

• Liver disease and other potentially hepatotoxic medications

• Current or recent opioid exposure

• New insomnia, agitation, anxiety, irritability, or mood worsening

• Pregnancy, lactation, and planned procedures

Do not abruptly stop an antidepressant to start LDN. Antidepressant discontinuation can produce physical and psychological symptoms and may increase relapse risk.

LDN Is Not Contrave

This distinction is essential because online conversations often use “naltrexone,” “LDN,” and “Contrave” as though they were interchangeable.

They are not.

Contrave is an FDA-approved extended-release combination containing 8 mg of naltrexone and 90 mg of bupropion per tablet. Its indication is chronic weight management in eligible adults, together with reduced-calorie nutrition and physical activity. Contrave is not approved to treat depression or another mental illness, even though bupropion is also an active ingredient in antidepressant products.

Contrave carries a boxed warning about suicidal thoughts and behaviors related to the antidepressant component, particularly in children, adolescents, and young adults. Its labeling also includes contraindications involving uncontrolled hypertension, seizure disorders, anorexia or bulimia, other bupropion-containing products, chronic opioid use, and certain abrupt medication or alcohol discontinuations.

The current label states that coadministration with another naltrexone-containing product is not recommended and that coadministration with another bupropion-containing product is contraindicated. Adding compounded LDN to Contrave should never be treated as a harmless way to “boost” mood or weight loss.

Review current Contrave prescribing information and read the Scripx comparison of LDN, Contrave, and GLP-1 therapy.

Mood Monitoring and Suicidality Require Direct Care

Oral naltrexone labeling notes postmarketing reports of depression, suicide, attempted suicide, and suicidal ideation in people treated for opioid dependence, while also stating that a causal relationship has not been demonstrated. The label advises monitoring for depression or suicidal thinking.

This point should not be distorted in either direction. The reports do not prove naltrexone caused the events, and they do not prove LDN prevents them. A person with new or worsening depression, agitation, unusual behavior, mania, self-harm thoughts, or suicidal thinking needs prompt clinical evaluation rather than an online medication experiment.

If you or someone you know is in suicidal crisis or emotional distress in the United States, call or text 988 or use the 988 Suicide & Crisis Lifeline. Call 911 or seek emergency care for immediate danger.

The Opioid Question Is a Major Safety Gate

Naltrexone blocks opioid receptors. Standard oral labeling contraindicates it in people receiving opioid analgesics, people currently dependent on opioids, and people in acute opioid withdrawal. Starting naltrexone after recent opioid exposure can precipitate severe withdrawal. Naltrexone can also make opioid pain medicines less effective.

The medication history should include more than scheduled pain pills. It should cover tramadol, codeine-containing cough products, opioid antidiarrheals, buprenorphine, methadone, intermittent prescriptions, nonmedical use, and medications that may be needed for surgery or dental care.

The label also warns that opioid tolerance may be lower after naltrexone is stopped, which can increase overdose vulnerability if a person returns to a previously tolerated opioid dose. Trying to overpower the blockade with more opioid can be fatal.

Do not start, stop, or time LDN around an opioid without a qualified prescriber. Depression, anxiety, substance-use disorders, chronic pain, and opioid exposure often overlap, making accurate disclosure especially important.

Review current oral naltrexone labeling.

Where GLP-1 Medications Fit

Semaglutide and tirzepatide may be prescribed for approved metabolic indications. They are not FDA-approved to treat depression or anxiety.

In January 2026, the FDA announced that its comprehensive review did not identify an increased risk of suicidal ideation or behavior with GLP-1 receptor agonists and requested removal of that warning from Wegovy, Zepbound, and Saxenda labeling. Current Wegovy and Zepbound prescribing information reflects that removal.

That is an important safety update. It is not evidence that GLP-1 medicines prevent depression, reduce anxiety, or treat suicidal thinking.

Mood can still change during weight-management treatment for many reasons. Nausea, vomiting, fatigue, reduced food or fluid intake, disrupted sleep, hypoglycemia in susceptible patients, rapid changes in body weight, expectations, body-image stress, and changes in other medications can all influence how a person feels. Depression and anxiety may also change independently of GLP-1 therapy.

GLP-1 medicines delay gastric emptying and may affect absorption of some oral medicines. Zepbound labeling specifically notes the potential to affect concomitant oral medications. This does not mean every antidepressant will become ineffective, but it supports symptom tracking and medication review when response changes after initiation or dose escalation.

There are no adequate controlled trials establishing LDN plus semaglutide or tirzepatide as a mood treatment or as an enhanced weight-loss combination. If both are prescribed, each should have a separate indication, safety plan, and measurable outcome.

Read the FDA's 2026 GLP-1 safety communication, current Wegovy labeling, and current Zepbound labeling.

Learn more about Scripx weight-management care.

What About Retatrutide and Mental Health?

Retatrutide is investigational and is not FDA-approved for any condition as of August 2026. The FDA states that retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition.

Early metabolic research should not be converted into claims that retatrutide improves depression, anxiety, reward pathways, or emotional well-being. Products advertised as “compounded retatrutide” are not a lawful or validated shortcut.

Review the FDA's warning about unapproved GLP-1 products and retatrutide.

What a Thoughtful LDN Evaluation Should Include

Before LDN is considered for someone who has depression, anxiety, chronic pain, autoimmune disease, or metabolic treatment, the care team should clarify:

1. The treatment goal. Is LDN being considered for pain, fatigue, another off-label condition, or a mental-health claim?

2. The psychiatric diagnosis and current severity. Depression, bipolar disorder, anxiety disorders, trauma, substance use, and medication effects require different plans.

3. Current treatment. Include psychotherapy, antidepressants, mood stabilizers, stimulants, antipsychotics, sleep medicines, and supplements.

4. Safety history. Review suicidal thinking, self-harm, mania, psychosis, seizure history, eating disorders, and significant alcohol or sedative use.

5. All opioid exposure. Include prescribed, intermittent, procedural, cough, antidiarrheal, and nonmedical sources.

6. Weight-management medications. Identify Contrave, bupropion-containing products, semaglutide, tirzepatide, and recent dose changes.

7. Medical contributors. Sleep, thyroid disease, anemia, nutrition, pain, pregnancy, liver disease, and other conditions may affect symptoms and safety.

8. Measurable outcomes. Use validated symptom scales, functional goals, sleep, adverse effects, and a defined reassessment date.

9. A crisis plan. Know who to contact for worsening symptoms, unusual behavior, self-harm thoughts, or immediate danger.

When a patient-specific low dose or dosage form is clinically necessary, a compounding pharmacy may prepare medication pursuant to a valid prescription. Compounded drugs are not FDA-approved, and the FDA does not evaluate them before marketing for safety, effectiveness, or quality. Formulation, source, quality systems, beyond-use dating, counseling, and care-team communication matter.

Learn about Scripx compounding services and what low-dose naltrexone is.

The Bottom Line

LDN for depression and anxiety remains an investigational idea, not an established treatment.

The 2017 proof-of-concept study was intriguing but included only 12 people, lasted three weeks, and did not meet statistical significance on its primary depression scale. The 2026 randomized trial included 37 people and found no meaningful advantage for adjunctive LDN over placebo at 12 weeks.

Anxiety evidence is weaker still. A survey in people with multiple sclerosis and secondary mood findings from other conditions cannot establish LDN as treatment for an anxiety disorder.

LDN is also not Contrave. Contrave is a naltrexone–bupropion weight-management product with its own boxed warning, contraindications, and interaction rules, and it is not approved to treat depression. Adding LDN to Contrave is not recommended by the product's naltrexone coadministration language.

The FDA's 2026 removal of suicidality warnings from Wegovy and Zepbound is reassuring, but it does not make GLP-1 medications antidepressants. LDN plus GLP-1 therapy has not been proven to improve mood or produce additional weight loss.

Ready for a coordinated medication review? Explore Scripx LDN care or contact Scripx. The goal is to define the indication, protect established mental-health treatment, identify opioid and Contrave conflicts, and measure outcomes honestly.

Medical disclaimer

This content is educational and is not medical advice, diagnosis, crisis counseling, or a prescription. LDN is used off label and is not FDA-approved for depression or anxiety. Do not start, stop, or change LDN, antidepressants, opioids, Contrave, bupropion, or GLP-1 therapy without guidance from a qualified clinician. If you are in suicidal crisis or emotional distress in the United States, call or text 988. Call 911 for immediate danger.

4. Frequently Asked Questions

Does low-dose naltrexone help depression?

It is not established. A 12-person pilot reported signals on some secondary depression scales, but its primary comparison was not statistically significant. A 2026 randomized trial involving 37 participants found that adjunctive LDN did not outperform placebo at 12 weeks.

Is LDN FDA-approved for depression or anxiety?

No. LDN is an off-label use of naltrexone. Naltrexone is not FDA-approved to treat depression, anxiety, or another mood disorder.

What did the 2026 LDN depression trial find?

Participants receiving LDN improved by an average of 10.5 MADRS points, while the placebo group improved by 9.8 points. The between-group difference was not statistically significant, with a reported p value of approximately 0.97.

Does LDN help anxiety?

There is no adequate randomized trial showing that LDN treats a primary anxiety disorder. A mailed survey in people with multiple sclerosis reported lower self-rated anxiety in some LDN groups, but the design cannot establish that LDN caused the difference.

Can LDN replace an antidepressant?

No evidence supports using LDN as a replacement for an antidepressant or psychotherapy. The direct depression studies evaluated LDN as an adjunct to existing antidepressant treatment.

Can I take LDN with an antidepressant?

Possibly in selected cases, but there is no universal answer. A clinician or pharmacist should review the exact antidepressant, other medications, liver health, seizure and bipolar history, opioid exposure, and treatment goal. Do not stop an antidepressant abruptly to start LDN.

Is LDN the same as Contrave?

No. Contrave is an FDA-approved extended-release combination of naltrexone and bupropion for chronic weight management in eligible adults. LDN is a smaller, customized, off-label dose of naltrexone without bupropion.

Does Contrave treat depression?

No. Although Contrave contains bupropion, its labeling states that Contrave is not approved to treat depression or another mental illness.

Can LDN be taken with Contrave?

Contrave labeling states that coadministration with other naltrexone-containing products is not recommended. Do not add LDN to Contrave without direct prescriber and pharmacist review.

Can LDN be taken with opioids?

This may block pain relief or precipitate severe withdrawal in an opioid-dependent person. Opioid exposure must be reviewed before LDN is prescribed, including tramadol, buprenorphine, methadone, cough medicines, and planned procedures.

Do semaglutide or tirzepatide cause suicidal thoughts?

In 2026, the FDA reported that its comprehensive review did not identify an increased risk of suicidal ideation or behavior with GLP-1 receptor agonists and requested removal of the warning from Wegovy and Zepbound labeling. Any new suicidal thinking still requires immediate clinical attention regardless of suspected cause.

Do GLP-1 medications treat depression or anxiety?

No GLP-1 medication is FDA-approved as an antidepressant or anxiety treatment. The removal of a safety warning does not establish a mental-health benefit.

Is LDN plus a GLP-1 proven to improve mood or weight loss?

No. There are no adequate controlled trials establishing the combination for depression, anxiety, or enhanced weight loss. Each medication needs a separate indication and monitoring plan.

Is retatrutide available for depression, anxiety, or weight loss?

Retatrutide remains investigational and is not FDA-approved for any condition as of August 2026. The FDA states that it cannot be used in compounding under federal law.